Home › Endometrial Cancer › New York
Endometrial Cancer clinical trials in New York
69 studies for Endometrial Cancer are looking for participants at sites in New York.
Cities in New York
- New York City52 studies
- Queens25 studies
- New Rochelle11 studies
- Staten Island11 studies
- Greenburgh11 studies
- Buffalo8 studies
- Syracuse7 studies
- The Bronx4 studies
- Rochester3 studies
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 8 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New York Long Island LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Northwell Health Imbert Cancer Center, Bay Shore
- Memorial Sloan Kettering Commack, Commack
- Northwell Health Physician Partners at Flushing, Flushing
- and 20 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074A Phase 1 Study of the Safety and Tolerability of CTX-10726
- START New York, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Roswell Park Cancer Institute IDS, Buffalo
- Memorial Sloan Kettering Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- The Woman's Health Pavilion, Howard Beach
- The Woman's Health Pavilion, Westbury
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Rochester, Rochester
- State University of New York Upstate Medical University, Syracuse
- Wilmot Cancer Institute at Webster, Webster
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Mineola
- Avenzo Therapeutics Recruiting Site, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, New York
- Research Site, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
Recruiting
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07270666Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Roswell Park Cancer Institute, Buffalo
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- and 4 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Commack
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- START New York-Long Island, Lake Success
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07262619Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study of Ivonescimab in People With Endometrial and Cervical Cancers
- Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 21, 2026 · NCT06925724A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 6055), Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004), New York
- Memorial Sloan Kettering Cancer Center ( Site 6053), New York
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health, New York
- SUNY Upstate Medical University, Syracuse
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06340568A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Commack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street, New York
- Perlmutter CC NYU Langone LI, New York
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- NYU Langone Health - Long Island, Mineola
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, New York
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07186842A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07227168Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore Einstein Comprehensive Cancer Center, The Bronx
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Laura & Isaac Perlmutter Cancer Center, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Mount Sinai Health System, New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Start - Ny, Long Island City
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- START Center for Cancer Research - Long Island New York, Lake Success
- Mount Sinai, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06840886A Study of MGC026 in Participants With Advanced Solid Tumors
- START-New York Long Island, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- Memorial Sloan Kettering Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingObservational study
Ages 18 and older · Women · Updated Aug 7, 2026 · NCT04291612Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- Roswell Park Comprehensive Care Center, Buffalo
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07444814From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.